Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.


Related Content

FDA Approvals, In Brief: Novartis’ Meningitis Vaccine Bexsero Gets Early Nod
Triferic’s Modified Indication Gets Past FDA Panel Despite Real World Applicability Concerns
Triferic’s ESA-Reduction Claim Draws FDA Skepticism Ahead Of ODAC Review
Rock-Solid Triferic Heads Toward ODAC Review
Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity
ESRD Market Snapshot: The Price Has To Be Right
AMAG Pharmaceuticals: Enough Irons In The Fire?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts